文献速递耳科与耳神经头颈外科

接受替妥木单抗治疗患者的耳科症状:一项多机构全国队列研究

Otologic Symptoms in Patients Treated With Teprotumumab: A Multi-Institutional National Cohort Study.
PubMed 文献 · Laryngoscope · 2025-08-15

本研究利用TriNetX多机构数据库,纳入美国成年甲状腺眼病(TED)患者,按倾向性评分匹配后各947例,比较使用与未使用替妥木单抗者的耳科结局。结果显示,替妥木单抗组感音神经性听力损失发生率为10.0%、耳鸣为5.6%,均高于未使用组的3.7%和1.8%,且风险显著增加。

要点

  • 替妥木单抗组感音神经性听力损失发生率为10.0%,未使用组为3.7%。
  • 替妥木单抗组耳鸣发生率为5.6%,未使用组为1.8%。
  • 使用替妥木单抗与感音神经性听力损失(OR 2.89)和耳鸣(OR 3.13)风险增加相关。

核心结论

  • 替妥木单抗的使用与甲状腺眼病患者发生感音神经性听力损失和耳鸣显著相关。
  • 接受替妥木单抗治疗的患者应监测耳科结局,以避免可能的不可逆损伤。
  • 需要进一步研究以建立标准化监测和治疗调整方案的临床指南。

研究设计与样本

  • 多机构全国队列研究,使用TriNetX多机构数据库查询美国成年(≥18岁)甲状腺眼病患者。
  • 使用倾向性评分按人口学和合并症匹配使用与未使用替妥木单抗的患者,匹配后每组各947例。
  • 结局基于ICD-10编码查询感音神经性听力损失和耳鸣,在TriNetX中计算比值比(OR)。

主要发现

  • 替妥木单抗组平均(标准差)年龄为56.4(14.7)岁,未使用组为48.4(17.6)岁。
  • 替妥木单抗组平均随访28.6(18.2)个月,未使用组平均随访26.8(21.3)个月。
  • 感音神经性听力损失发生率在替妥木单抗组为10.0%,未使用组为3.7%。
  • 耳鸣发生率在替妥木单抗组为5.6%,未使用组为1.8%。
  • 与未使用替妥木单抗的甲状腺眼病患者相比,使用替妥木单抗者感音神经性听力损失的OR为2.89(95% CI: 1.92-4.36),耳鸣的OR为3.13(95% CI: 1.79-5.46)。

临床怎么用

  • 作者认为,接受替妥木单抗治疗的患者应监测耳科结局,以避免可能的不可逆损伤。
  • 作者指出,需要进一步研究以建立标准化监测和治疗调整方案的临床指南。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Teprotumumab is a monoclonal antibody introduced in 2020 to treat thyroid eye disease (TED) with potential adverse effects on the cochlea and fat tissue around the eustachian tube. This study investigates the incidence and odds of developing hearing loss and tinnitus associated with Teprotumumab. METHODS: TriNetX, a multi-institutional database, was queried for U.S. adults (≥ 18 years) with TED. Patients who were and were not prescribed Teprotumumab were matched using a propensity score by demographics and comorbidities. Outcomes were queried based on ICD-10 codes for sensorineural hearing loss (SNHL) and tinnitus. Odds ratios (OR) were calculated in TriNetX. RESULTS: A total of 947 TED patients used Teprotumumab (mean [S.D.] age 56.4 [14.7]) while 258 520 TED patients did not (age 48.4 [17.6]). After propensity score matching, each analytic cohort included 947 patients. At a mean follow-up of 28.6 (18.2) months (S.D.) for the Teprotumumab group and 26.8 (21.3) months (S.D.) for the non-use group, the incidence of SNHL was 10.0% and 3.7%, respectively. Tinnitus incidence rates were 5.6% in the Teprotumumab group and 1.8% in the non-use group. TED patients treated with Teprotumumab demonstrated higher odds of SNHL (OR, 2.89; 95% CI:1.92-4.36) and tinnitus (OR, 3.13; 95% CI:1.79-5.46) compared to TED patients not treated with Teprotumumab. CONCLUSION: Teprotumumab use is significantly associated with the development of SNHL and tinnitus among TED patients. Patients receiving Teprotumumab should be monitored for otologic outcomes to avoid possible irreversible damage. Further research is needed to establish clinical guidelines for standardized monitoring and treatment adjustment protocols.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Hori K, Wenger T, Davuluru S, et al. Otologic Symptoms in Patients Treated With Teprotumumab: A Multi-Institutional National Cohort Study. Laryngoscope. 2025. PMID: 40814274. doi:10.1002/lary.70045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。